AU2013323861C1 - Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer - Google Patents

Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Download PDF

Info

Publication number
AU2013323861C1
AU2013323861C1 AU2013323861A AU2013323861A AU2013323861C1 AU 2013323861 C1 AU2013323861 C1 AU 2013323861C1 AU 2013323861 A AU2013323861 A AU 2013323861A AU 2013323861 A AU2013323861 A AU 2013323861A AU 2013323861 C1 AU2013323861 C1 AU 2013323861C1
Authority
AU
Australia
Prior art keywords
per day
male human
oxo
cyano
oct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013323861A
Other languages
English (en)
Other versions
AU2013323861A1 (en
AU2013323861B2 (en
Inventor
Isan CHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aragon Pharmaceuticals Inc
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49293921&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013323861(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Publication of AU2013323861A1 publication Critical patent/AU2013323861A1/en
Application granted granted Critical
Publication of AU2013323861B2 publication Critical patent/AU2013323861B2/en
Priority to AU2018206695A priority Critical patent/AU2018206695C1/en
Priority to AU2020244431A priority patent/AU2020244431A1/en
Publication of AU2013323861C1 publication Critical patent/AU2013323861C1/en
Priority to AU2024204555A priority patent/AU2024204555A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
AU2013323861A 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer Active AU2013323861C1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2018206695A AU2018206695C1 (en) 2012-09-26 2018-07-16 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AU2020244431A AU2020244431A1 (en) 2012-09-26 2020-09-29 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AU2024204555A AU2024204555A1 (en) 2012-09-26 2024-07-01 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705900P 2012-09-26 2012-09-26
US61/705,900 2012-09-26
PCT/US2013/061197 WO2014052237A1 (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018206695A Division AU2018206695C1 (en) 2012-09-26 2018-07-16 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Publications (3)

Publication Number Publication Date
AU2013323861A1 AU2013323861A1 (en) 2015-04-02
AU2013323861B2 AU2013323861B2 (en) 2018-04-19
AU2013323861C1 true AU2013323861C1 (en) 2024-05-02

Family

ID=49293921

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2013323861A Active AU2013323861C1 (en) 2012-09-26 2013-09-23 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AU2018206695A Ceased AU2018206695C1 (en) 2012-09-26 2018-07-16 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AU2020244431A Abandoned AU2020244431A1 (en) 2012-09-26 2020-09-29 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AU2024204555A Pending AU2024204555A1 (en) 2012-09-26 2024-07-01 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2018206695A Ceased AU2018206695C1 (en) 2012-09-26 2018-07-16 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AU2020244431A Abandoned AU2020244431A1 (en) 2012-09-26 2020-09-29 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
AU2024204555A Pending AU2024204555A1 (en) 2012-09-26 2024-07-01 Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Country Status (36)

Country Link
US (8) US9884054B2 (enExample)
EP (3) EP3777845A1 (enExample)
JP (4) JP6351597B2 (enExample)
KR (3) KR20220025231A (enExample)
CN (4) CN104661658A (enExample)
AU (4) AU2013323861C1 (enExample)
BR (1) BR112015006705A8 (enExample)
CA (1) CA2885415C (enExample)
CL (1) CL2015000715A1 (enExample)
CR (1) CR20150140A (enExample)
CY (1) CY1123716T1 (enExample)
DK (1) DK3305285T3 (enExample)
EA (3) EA037806B1 (enExample)
EC (1) ECSP15011764A (enExample)
ES (1) ES2836424T3 (enExample)
GT (1) GT201500071A (enExample)
HK (1) HK1212221A1 (enExample)
HR (1) HRP20201721T1 (enExample)
HU (1) HUE051211T2 (enExample)
IL (3) IL237692B2 (enExample)
IN (1) IN2015DN02387A (enExample)
LT (1) LT3305285T (enExample)
MX (2) MX379847B (enExample)
MY (1) MY180834A (enExample)
NI (1) NI201500042A (enExample)
NZ (3) NZ745682A (enExample)
PE (1) PE20150765A1 (enExample)
PH (3) PH12018502570B1 (enExample)
PT (1) PT3305285T (enExample)
RS (1) RS60976B1 (enExample)
SG (3) SG11201501870RA (enExample)
SI (1) SI3305285T1 (enExample)
SM (1) SMT202000573T1 (enExample)
UA (3) UA124967C2 (enExample)
WO (1) WO2014052237A1 (enExample)
ZA (1) ZA201808499B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028869B1 (ru) 2010-02-16 2018-01-31 Арагон Фармасьютикалс, Инк. Модуляторы рецептора андрогенов и их применение
PE20150099A1 (es) 2011-12-16 2015-01-30 Olema Pharmaceuticals Inc Compuestos novedosos de benzopirano, composiciones y usos de los mismos
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
LT3226842T (lt) * 2014-12-05 2021-03-25 Aragon Pharmaceuticals, Inc. Priešvėžinės kompozicijos
CN114886852A (zh) * 2014-12-05 2022-08-12 阿拉贡药品公司 抗癌组合物
JP6830892B2 (ja) * 2014-12-05 2021-02-17 アラゴン ファーマシューティカルズ，インコーポレイテッド 抗癌性組成物
KR101718226B1 (ko) 2015-08-05 2017-03-20 울산대학교 산학협력단 사쿠라소사포닌 화합물을 유효성분으로 포함하는 안드로겐 수용체 관련 질환의 예방 또는 치료용 조성물
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
ES3014630T3 (en) * 2016-07-29 2025-04-23 Janssen Pharmaceutica Nv Niraparib for use in a method of treating prostate cancer
MX2020003845A (es) * 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
WO2020157699A1 (en) 2019-01-30 2020-08-06 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
US11723898B2 (en) * 2019-11-04 2023-08-15 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment

Family Cites Families (182)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE550650A (enExample) 1955-08-30
JPS4916937B1 (enExample) 1970-01-21 1974-04-25
US3823240A (en) 1970-10-06 1974-07-09 Rhone Poulenc Sa Fungicidal hydantoin derivatives
GB1472467A (en) 1974-04-19 1977-05-04 Wyeth John & Brother Ltd Thiohydantoins
FR2329276A1 (fr) 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE2614831A1 (de) 1976-04-06 1977-10-20 Bayer Ag 1,3,4-thiadiazolylderivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
CA1138334A (en) 1977-10-28 1982-12-28 Karl Bernauer Pharmaceutical preparations containing certain urea derivatives
MC1220A1 (fr) 1977-10-28 1979-07-20 Hoffmann La Roche Nouveaux derives d'imidazolidine
AU531493B2 (en) 1977-12-01 1983-08-25 The Wellcome Foundation Limited Thiohydantion derivatives
EP0004723A1 (en) 1978-03-30 1979-10-17 Beecham Group Plc Deoxyhydantoins, processes for their preparation and pharmaceutical compositions containing them
FR2449448B1 (fr) 1979-02-20 1983-05-27 Inst Nat Radio Elements Composition pharmaceutique comprenant un derive de phenylhydantoine, derives mis en oeuvre et leur preparation
FI801184A7 (fi) 1979-04-24 1981-01-01 F Hoffmann La Roche & Co Menetelmä imidatsolidiini-johdannaisten valmistamiseksi.
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS57197268A (en) 1981-05-29 1982-12-03 Sumitomo Chem Co Ltd Substituted phenylhydantoin derivative, its preparation, and herbicide containing the same as active ingredient
EP0091596B1 (de) 1982-04-08 1991-09-11 Shell Internationale Researchmaatschappij B.V. Neue Hydantoine, ihre Herstellung und Verwendung
US4473393A (en) 1982-08-06 1984-09-25 Buffalo Color Corporation Pesticidal thiohydantoin compositions
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
JPS59210083A (ja) 1983-05-13 1984-11-28 Otsuka Chem Co Ltd １，３，４−チアジアゾ−ル−５−オン誘導体、その製造法及び該誘導体を有効成分とする除草剤
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS6092285A (ja) 1983-10-26 1985-05-23 Shionogi & Co Ltd イソオキサゾ−ル系環状尿素類
JPS6098878U (ja) 1983-12-10 1985-07-05 リズム時計工業株式会社 液晶表示装置
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPS60239737A (ja) 1984-05-14 1985-11-28 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料
JPH0219363Y2 (enExample) 1985-07-31 1990-05-29
EP0230654B1 (en) 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
DE3604042A1 (de) 1986-02-08 1987-08-13 Hoechst Ag Imidazolidin(thi)on-derivate, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
JPS649978A (en) 1987-07-02 1989-01-13 Shionogi & Co Perfluoroalkylisoxazole derivative
US4859228A (en) 1987-07-16 1989-08-22 Ici Americas Inc Novel 5-aminomethylene-2,4-imidazolidinediones and 5-aminomethylene-2-thionoimidazolidine-4-ones
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
FR2619381B1 (fr) 1987-08-13 1989-12-08 Roussel Uclaf Nouvelles imidazolidines substituees par un radical hydroxymethyle et un radical phenyl substitue, leur procede de preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant et un intermediaire pour leur preparation
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
CA1331757C (en) 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5614620A (en) 1988-03-30 1997-03-25 Arch Development Corporation DNA binding proteins including androgen receptor
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US6307030B1 (en) 1988-04-15 2001-10-23 The University Of North Carolina At Chapel Hill Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions
JPH0219363A (ja) 1988-07-06 1990-01-23 Fujisawa Pharmaceut Co Ltd イミダゾリジン誘導体
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DE3835168A1 (de) 1988-10-15 1990-04-19 Bayer Ag N-aryl-stickstoffheterocyclen, mehrere verfahren zu ihrer herstellung und ihre verwendung als herbizide
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
FR2656302B1 (fr) 1989-12-22 1992-05-07 Roussel Uclaf Nouveau procede de preparation de l'anandron et derives de l'anandron.
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
USRE35956E (en) 1991-01-09 1998-11-10 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
FR2693461B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
JP2845384B2 (ja) 1991-11-14 1999-01-13 キヤノン株式会社 画像処理装置
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5346913A (en) 1992-05-26 1994-09-13 Rohm And Haas Company N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
FR2694290B1 (fr) 1992-07-08 1994-09-02 Roussel Uclaf Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
DE4316542C1 (de) 1993-05-18 1994-07-21 Schaefer Micomed Gmbh Osteosynthesevorrichtung
FR2715402B1 (fr) 1994-01-05 1996-10-04 Roussel Uclaf Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) 1994-01-05 2003-02-21 Hoechst Marion Roussel Inc New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
WO1995019770A1 (en) 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US6124211A (en) 1994-06-14 2000-09-26 Fsi International, Inc. Cleaning method
JPH089997A (ja) 1994-06-28 1996-01-16 Shimadzu Corp 核酸合成法およびそれに用いる試薬キット
WO1996004248A1 (en) 1994-07-29 1996-02-15 Suntory Limited Imidazolidine derivative and use thereof
FR2725206B1 (fr) 1994-09-29 1996-12-06 Roussel Uclaf Nouvelles imidazolidines substituees par un heterocycle, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
US5656651A (en) 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
DE19540027A1 (de) 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
FR2741346B1 (fr) 1995-11-16 1997-12-19 Roussel Uclaf Nouveau procede de preparation de derives phenylimidazolidine
FR2741342B1 (fr) 1995-11-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
EP0876354A1 (en) 1995-11-28 1998-11-11 American Home Products Corporation 2-(substituted sulfanyl)-3,5-dihydro-imidazol-4-one derivatives
TW418195B (en) 1995-11-28 2001-01-11 American Home Prod 2-thioxo-imidazolidin-4-one derivatives
US5554607A (en) 1995-11-28 1996-09-10 American Home Products Corporation Use of 2-thioxo-imidazolin-4-one derivatives in the treatment of atherosclerosis
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5780435A (en) 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
FR2742749B1 (fr) 1995-12-22 1998-02-06 Roussel Uclaf Nouvelles phenylimidazolidines comportant notamment un radical nitrooxy ou carbonyloxy, procede et intermediaires de preparation, application comme medicaments, nouvelles utilisations et compositions pharmaceutiques
US6489163B1 (en) 1996-05-08 2002-12-03 Board Of Regents, The University Of Texas System Ribozyme mediated inactivation of the androgen receptor
JP3697320B2 (ja) 1996-06-20 2005-09-21 株式会社日立製作所 光ファイバセンサ
DK1007080T3 (da) 1996-08-30 2007-07-30 Peptech Ltd Formulering til vedvarende frigivelse af peptidagonister og analoger af GnRH
US5726061A (en) 1996-10-08 1998-03-10 Smithkline Beechum Corporation Method of diagnosing and monitoring colorectal cancer
US7053263B2 (en) 1996-10-15 2006-05-30 The Regents Of The University Of California Mouse models of human prostate cancer progression
JP2001511146A (ja) 1997-02-03 2001-08-07 ダウ・アグロサイエンス・エル・エル・シー 殺菌・殺カビ剤としてのピリジン環上にカルボン酸誘導基を有する２−メトキシイミノ−２−（ピリジニルオキシメチル）フェニルアセトアミド
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6506607B1 (en) 1997-12-24 2003-01-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the identification and assessment of prostate cancer therapies and the diagnosis of prostate cancer
WO1999065494A1 (en) 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
BR9914018A (pt) 1998-09-22 2001-07-03 Yamanouchi Pharmaceuticals Co Derivado de cianofenila
ATE240944T1 (de) 1998-09-22 2003-06-15 Degussa Verfahren zur herstellung von imidazolidin-2,4- dionen
WO2000026195A1 (en) 1998-10-30 2000-05-11 G.D. Searle & Co. Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
WO2000044731A1 (en) 1999-01-27 2000-08-03 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
WO2001007048A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6479063B2 (en) 1999-12-27 2002-11-12 Kenneth Weisman Therapeutic uses of hormonal manipulation using combinations of various agents to treat atherosclerosis
GB0008368D0 (en) 2000-04-06 2000-05-24 Astrazeneca Ab Combination product
EP1302471B1 (en) 2000-05-31 2006-12-27 Mitsui Chemicals, Inc. Sulfur compound and use thereof
ES2284641T3 (es) 2000-05-31 2007-11-16 Tanabe Seiyaku Co., Ltd. Inhibidores de la adhesion celular mediada por alfa-l-beta-2.
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
US20040077605A1 (en) 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
WO2002053155A1 (en) 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
US6710037B2 (en) 2001-05-01 2004-03-23 Schering Corporation Method of treating androgen-dependent disorders
CN1596253A (zh) 2001-10-01 2005-03-16 布里斯托尔-迈尔斯斯奎布公司 用作抗炎药的螺－乙内酰脲化合物
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
US6861432B2 (en) 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
GB0200283D0 (en) 2002-01-08 2002-02-20 Smithkline Beecham Plc Compounds
DE10218963A1 (de) 2002-04-27 2003-11-20 Aventis Pharma Gmbh Zubereitungen zur topischen Applikation von antiandrogen wirksamen Substanzen
TW200407324A (en) 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
WO2004016758A2 (en) 2002-08-15 2004-02-26 Genzyme Corporation Brain endothelial cell expression patterns
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
FR2845384B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
FR2845385B1 (fr) 2002-10-04 2004-12-31 Fournier Lab Sa Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique
JP2006504795A (ja) 2002-10-03 2006-02-09 サイプレス バイオサイエンス， インコーポレイテッド 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
CA2500977A1 (en) 2002-10-04 2004-04-15 Laboratoires Fournier S.A. 2-thiohydantoine derivative compounds and use thereof in therapeutics
UA79504C2 (en) 2002-11-07 2007-06-25 Organon Nv Indols for treating diseases associated with androgen receptors
FR2850652B1 (fr) 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2004252175A (ja) 2003-02-20 2004-09-09 Kyocera Mita Corp 現像装置、画像形成装置および現像剤の回収方法
BRPI0411083A (pt) 2003-06-12 2006-07-25 Astellas Pharma Inc derivado de benzamida ou sais do mesmo
EP1636205A1 (en) 2003-06-12 2006-03-22 Novo Nordisk A/S Pyridinyl carbamates as hormone-sensitive lipase inhibitors
EP1634874A4 (en) 2003-06-12 2008-04-02 Chugai Pharmaceutical Co Ltd imidazolidine
TW200523252A (en) 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
EP1709152A4 (en) 2003-12-15 2007-11-07 Univ California MOLECULAR SIGNATURE OF PTEN TUMOR SUPPRESSOR
DE602004031881D1 (de) 2003-12-19 2011-04-28 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
WO2005099693A2 (en) 2004-02-24 2005-10-27 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies and compounds
WO2005089752A2 (en) 2004-03-15 2005-09-29 Ptc Therapeutics, Inc. Tetra-cyclic carboline derivatives for inhibiting angiogenesis
EP1621536A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
JP4912148B2 (ja) 2004-08-03 2012-04-11 中外製薬株式会社 新規イミダゾリジン誘導体
EP1790640A4 (en) 2004-09-09 2009-07-29 Chugai Pharmaceutical Co Ltd NEW IMIDAZOLIDINE DERIVATIVE AND APPLICATION THEREOF
WO2006027266A1 (en) 2004-09-10 2006-03-16 Nitec Pharma Ag Tablets with site time-controlled gastrointestinal release of active ingredient
AR053690A1 (es) 2005-03-23 2007-05-16 Pfizer Prod Inc Terapia de cancer de prostata con anticuerpos contra ctla4 y terapia hormonal
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
KR101782236B1 (ko) 2005-05-13 2017-09-26 더 리전트 오브 더 유니버시티 오브 캘리포니아 디아릴히단토인 화합물
AR054849A1 (es) 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
FR2889189A1 (fr) 2005-07-28 2007-02-02 Cerep Sa Composes derives d'hydantoine et leur utilistion en tant qu'antagonistes de mchr-1
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CN101032486B (zh) 2006-03-08 2011-05-11 张宏 逆转唑类药物抗真菌活性多药耐药性的药用植物增效剂
CN101032483B (zh) 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
PT2368550E (pt) 2006-03-27 2013-12-03 Univ California Modulador do receptor de androgénios para o tratamento de cancro da próstata e doenças associadas ao receptor de androgénios
CN101460467B (zh) 2006-03-29 2012-09-19 加利福尼亚大学董事会 二芳基硫代乙内酰脲化合物
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
CN101528309A (zh) 2006-08-25 2009-09-09 库伽尔生物科技公司 包括给予维生素d化合物和另外的治疗剂的治疗癌症的方法
RS52956B (sr) 2006-08-25 2014-02-28 Janssen Oncology Inc. Kompozicije za tretman kancera
EP1905439A1 (en) 2006-09-24 2008-04-02 GPC Biotech AG Second line treatment of metastatic hormone refractory prostate cancer using satraplatin
JP4993996B2 (ja) 2006-10-20 2012-08-08 フクダ電子株式会社 輸液ポンプモニタリング装置
US8461343B2 (en) 2007-03-27 2013-06-11 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
UY31432A1 (es) 2007-10-26 2009-05-29 Compuestos de diarilhidantoina
JP2011503075A (ja) 2007-11-09 2011-01-27 ノバルティス アーゲー エポチロンまたはエポチロン誘導体誘発下痢を処置するためのコルチコステロイド
TWI442932B (zh) 2008-02-11 2014-07-01 Ferring Int Ct Sa 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法
US20140187641A1 (en) * 2012-08-23 2014-07-03 Gtx Estrogen receptor ligands and methods of use thereof
CA2753425A1 (en) 2009-02-24 2010-09-02 Medivation Prostate Therapeutics, Inc. Specific diarylhydantoin and diarylthiohydantoin compounds
WO2010124826A1 (en) * 2009-04-29 2010-11-04 Bayer Schering Pharma Aktiengesellschaft Substituted imidazoquinoxalines
EA028869B1 (ru) 2010-02-16 2018-01-31 Арагон Фармасьютикалс, Инк. Модуляторы рецептора андрогенов и их применение
SI2538785T1 (en) 2010-02-24 2018-05-31 Medivation Prostate Therapeutics Llc Methods for the synthesis of diarylthiohidantoin and diarylhydantoin compounds
AU2011285724B2 (en) 2010-08-04 2015-01-22 Pellficure Pharmaceuticals, Inc. Combination therapy for the treatment of prostate carcinoma
US20130253035A1 (en) * 2010-08-16 2013-09-26 Duke University Camkk-beta as a target for treating cancer
US9314473B2 (en) * 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
WO2012142208A1 (en) 2011-04-13 2012-10-18 The Trustees Of The University Of Pennsylvania Bifunctional akr1c3 inhibitors/androgen receptor modulators and methods of use thereof
WO2012145330A1 (en) 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
EP2709614A4 (en) 2011-05-17 2015-04-15 Takeda Pharmaceutical PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER
CN103997894B (zh) 2011-07-29 2016-08-24 麦迪韦逊前列腺治疗股份有限公司 乳癌的治疗
US20130045204A1 (en) * 2011-08-19 2013-02-21 The University Of British Columbia Fluorinated bisphenol ether compounds and methods for their use
US20130079241A1 (en) * 2011-09-15 2013-03-28 Jianhua Luo Methods for Diagnosing Prostate Cancer and Predicting Prostate Cancer Relapse
PL2785349T5 (pl) * 2011-11-30 2023-01-30 Astrazeneca Ab Kombinacja do leczenia nowotworu
PL3912626T3 (pl) 2012-02-24 2025-01-20 The University Of Chicago Sposoby i kompozycje dotyczące antagonizmu wobec receptora glukokortykoidowego i nowotworu prostaty
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
FR2989357B1 (fr) 2012-04-12 2016-02-05 Allia Conditionnement unique pour un ensemble sanitaire comprenant une cuvette de wc suspendu et un bati-support associe
JP6182209B2 (ja) 2012-06-07 2017-08-16 アラゴン ファーマシューティカルズ，インコーポレイテッド アンドロゲン受容体変調剤の結晶質形態
RS62676B1 (sr) 2012-09-11 2021-12-31 Medivation Prostate Therapeutics Llc Formulacije enzalutamida
MY180834A (en) 2012-09-26 2020-12-10 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
SMT201900021T1 (it) 2013-04-23 2019-02-28 Zx Pharma Llc Composizione gastroresistente a base di multiparticolato con sottorivestimento proteinaceo
JP2014239737A (ja) 2013-06-11 2014-12-25 株式会社ジェイテクト 個人認証装置および車両用個人認証システム
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
CN105916501A (zh) 2013-12-06 2016-08-31 豪夫迈·罗氏有限公司 用于治疗局部晚期或转移性雌激素受体阳性乳腺癌的雌激素受体调节剂
MX386859B (es) 2014-02-05 2025-03-19 Lek Pharmaceuticals Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
CN114886852A (zh) 2014-12-05 2022-08-12 阿拉贡药品公司 抗癌组合物
JP6830892B2 (ja) 2014-12-05 2021-02-17 アラゴン ファーマシューティカルズ，インコーポレイテッド 抗癌性組成物
LT3226842T (lt) 2014-12-05 2021-03-25 Aragon Pharmaceuticals, Inc. Priešvėžinės kompozicijos
CN104857157A (zh) 2015-05-12 2015-08-26 四川金堂海纳生物医药技术研究所 一种治疗子宫内膜增殖症的汤剂药物及制备方法
MX2020003845A (es) 2017-10-16 2020-11-06 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración.
JP7085410B2 (ja) 2018-06-01 2022-06-16 太 小林 テープ巻取り用治具及び小巻テープ
WO2020157699A1 (en) 2019-01-30 2020-08-06 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
CN119230570A (zh) 2023-06-29 2024-12-31 三星电子株式会社 图像传感器

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CLEGG NICOLA J ET AL, "ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment", CANCER RESEARCH, (201203), vol. 72, no. 6, ISSN 0008-5472, pages 1494 - 1503 *
Dana E. Rathkopf ET AL, J. Clin. Oncol. 30, Suppl. Abstr. 4548, (20120530), URL:http://jco.ascopubs.org/gca?gca=ascomtg%3B30%2F15_suppl%2F4548&allch=citmgr&submit=Go, (20131209) *
Liu Alvin Y et al. "Lineage relationship between LNCaP and LNCaPderived prostate cancer cell lines", Prostate, 60(2), 98-108, July 1, 2004. *
RATHKOPF D E (CORRESPONDENCE) ET AL, JOURNAL OF CLINICAL ONCOLOGY; ASCO ANNUAL MEETING 2011, vol. 29, no. 15, SUPPL. 1, page TPS190 *
REAGAN-SHAW S ET AL, "Dose translation from animal to human studies revisited", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, US, (20070101), vol. 22, ISSN 0892-6638, pages 659 - 661 *
SMITH M R ET AL, "ARN-509 IN MEN WITH HIGH RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER", ANNALS OF ONCOLOGY; ABSTRACT BOOK OF THE 37TH ESMO CONGRESS, (20120901), vol. 23, no. Suppl. 9, page 303 *
TRAN CHRIS ET AL, "Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer", SCIENCE (WASHINGTON D C), (200905), vol. 324, no. 5928, ISSN 0036-8075, pages 787 - 790 *

Also Published As

Publication number Publication date
PH12015500615A1 (en) 2015-05-11
EA201590650A1 (ru) 2015-07-30
CA2885415A1 (en) 2014-04-03
SG10201912719TA (en) 2020-02-27
EA201890598A3 (ru) 2019-03-29
BR112015006705A2 (pt) 2017-07-04
MX2015003909A (es) 2016-01-08
LT3305285T (lt) 2020-12-10
CY1123716T1 (el) 2022-03-24
US10799488B2 (en) 2020-10-13
EA202190820A1 (ru) 2021-10-29
US20180110764A1 (en) 2018-04-26
PH12018502569A1 (en) 2020-12-07
PH12018502570B1 (en) 2023-03-10
PH12018502570A1 (en) 2020-12-07
WO2014052237A1 (en) 2014-04-03
ES2836424T3 (es) 2021-06-25
IL312316A (en) 2024-06-01
US20190269667A1 (en) 2019-09-05
JP6527621B2 (ja) 2019-06-05
MX2019010098A (es) 2019-10-15
AU2024204555A1 (en) 2024-07-18
NZ744456A (en) 2019-09-27
NZ745682A (en) 2019-09-27
CN115737643A (zh) 2023-03-07
HRP20201721T1 (hr) 2021-02-19
JP2021130718A (ja) 2021-09-09
US20180318277A1 (en) 2018-11-08
CR20150140A (es) 2015-06-11
US20140088129A1 (en) 2014-03-27
JP2019163288A (ja) 2019-09-26
US20210000812A1 (en) 2021-01-07
AU2013323861A1 (en) 2015-04-02
EP3305285B1 (en) 2020-09-02
HK1252867A1 (en) 2019-06-06
PH12015500615B1 (en) 2019-02-20
ZA201808499B (en) 2022-12-21
JP6351597B2 (ja) 2018-07-04
GT201500071A (es) 2015-12-31
CN104661658A (zh) 2015-05-27
US10849888B2 (en) 2020-12-01
AU2018206695B2 (en) 2020-07-02
NI201500042A (es) 2015-09-02
AU2018206695C1 (en) 2020-10-22
AU2018206695A1 (en) 2018-08-02
PT3305285T (pt) 2020-11-24
EA201890598A2 (ru) 2018-07-31
SG11201501870RA (en) 2015-04-29
EP3777845A1 (en) 2021-02-17
JP2018150365A (ja) 2018-09-27
MY180834A (en) 2020-12-10
UA117663C2 (uk) 2018-09-10
BR112015006705A8 (pt) 2019-08-27
IL304337A (en) 2023-09-01
IN2015DN02387A (enExample) 2015-09-04
IL237692A0 (en) 2015-05-31
SI3305285T1 (sl) 2021-03-31
CN109999036A (zh) 2019-07-12
IL237692B2 (en) 2024-07-01
US20190269668A1 (en) 2019-09-05
IL237692B1 (en) 2023-08-01
DK3305285T3 (da) 2020-10-26
EP2900224A1 (en) 2015-08-05
AU2020244431A1 (en) 2020-10-29
UA124967C2 (uk) 2021-12-22
CA2885415C (en) 2021-06-29
US10799489B2 (en) 2020-10-13
SG10201902568YA (en) 2019-04-29
KR102210825B1 (ko) 2021-02-01
CN109908114A (zh) 2019-06-21
KR20150070192A (ko) 2015-06-24
KR20220025231A (ko) 2022-03-03
AU2013323861B2 (en) 2018-04-19
EP3305285A1 (en) 2018-04-11
EA037806B1 (ru) 2021-05-24
USRE49353E1 (en) 2023-01-03
HUE051211T2 (hu) 2021-03-01
CL2015000715A1 (es) 2015-12-11
US10052314B2 (en) 2018-08-21
EA030128B1 (ru) 2018-06-29
JP2015531373A (ja) 2015-11-02
JP7198310B2 (ja) 2022-12-28
US9884054B2 (en) 2018-02-06
SMT202000573T1 (it) 2020-11-10
JP6896016B2 (ja) 2021-06-30
NZ705815A (en) 2018-08-31
RS60976B1 (sr) 2020-11-30
PE20150765A1 (es) 2015-05-15
MX371020B (es) 2020-01-13
UA129494C2 (uk) 2025-05-14
MX379847B (es) 2025-03-11
HK1212221A1 (en) 2016-06-10
USRE50642E1 (en) 2025-10-21
ECSP15011764A (es) 2016-01-29
KR20210013342A (ko) 2021-02-03

Similar Documents

Publication Publication Date Title
USRE50642E1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
HK1252867B (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
EA050383B1 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты

Legal Events

Date Code Title Description
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO MEET THE REQUIREMENT OF THE GRACE PERIOD HAS BEEN EXTENDED TO 17 OCT 2013

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 APR 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 APR 2018

FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 DEC 2023

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 14 DEC 2023